Miami-based Deborah Mash is a neuroscientist and pharmacologist. She was the first to conduct clinical studies of Ibogaine for substance use disorders and her laboratory identified noribogaine as a pharmacologically active metabolite. Mash is a co-founder of DemeRx Inc., a clinical stage drug development company currently advancing noribogaine, the active metabolite of ibogaine for the treatment for alcohol use disorder and opioid dependence.
Mash received her Ph.D. in Pharmacology from the University of Miami Leonard M. Miller School of Medicine. She completed a fellowship in Neurology and Neuroanatomy at Beth Israel Hospital, Harvard Medical School. She is nationally recognized as a leading researcher in the fields of addiction neurobiology, genomics, and psychedelic medicine, playing a pivotal role in over 300 published studies. She is Professor Emerita of Neurology and Molecular and Cellular Pharmacology, University of Miami School of Medicine.